US protection

US protection ending in 2027: Injuries

As of the edition of 20 October 2026, 16 drugs have US protection that ends in 2027 in injuries; 10 of them have at least one company on route B because of it.

Sources: FDA Orange Book and Purple Book, other approval registers.

16 drugs

DrugUS protectionStatusHolderTargetRoute B rows
Anakinra Ends 2027 (orphan exclusivity)Marketed Swedish Orphan Biovitrum IL1R1 0
Bevacizumab Ends 2027 (orphan exclusivity)Marketed Roche VEGFA 2
Edoxaban Ends 2027 (patent)Marketed Daiichi Sankyo F10 1
Enzalutamide Ends 2027 (patent)Marketed Astellas AR 1
Ferric carboxymaltose Ends 2027 (patent)Marketed American Regent 0
Fidaxomicin Ends 2027 (patent)Marketed Merck & Co. 0
Florbetapir Ends 2027 (patent)Marketed Avid Radiopharmaceuticals 0
Ipilimumab Ends 2027 (orphan exclusivity)Marketed Bristol Myers Squibb CTLA4 1
Lenalidomide Ends 2027 (patent)Marketed Bristol Myers Squibb CRBN 0
Methylene blue cation Ends 2027 (exclusivity)Marketed Provepharm GUCY1A1, GUCY1A2, GUCY1B1 1
Nintedanib Ends 2027 (exclusivity)Marketed Boehringer Ingelheim FGFR1, FGFR2, FGFR3 9
Pantoprazole Ends 2027 (exclusivity)Marketed Pfizer ATP4A 1
Parathyroid hormone Ends 2027 (computed from the first US licence)Marketed Takeda PTH1R 1
Sacubitril Ends 2027 (patent)Marketed Novartis MME 1
Secukinumab Ends 2027 (computed from the first US licence)Marketed Novartis IL17A 1
Telavancin Ends 2027 (patent)Marketed Apotex 0

Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.

Which companies are on route B in 2027 in injuries

In the product

10 of these 16 drugs have at least one company on route B. Which companies, and their scores, are in the product.

Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.

US protection movers, once a month

The drugs that entered or left the two-year window in the latest edition. An email, not an account: it gives no access to the product.